EAAT2 (Excitatory Amino Acid Transporter 2), also known as GLT-1 (Glutamate Transporter 1), is the predominant glutamate transporter in the central nervous system, responsible for the vast majority of glutamate reuptake from the synaptic cleft[1]. Located primarily on astrocytes, EAAT2 maintains extracellular glutamate concentrations below toxic levels and prevents excitotoxicity—a key pathological mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and the tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[2].
EAAT2 dysfunction or downregulation contributes to chronic glutamate accumulation, neuronal excitotoxicity, and progressive neurodegeneration. Therapeutic strategies aimed at restoring EAAT2 expression and function represent a promising approach to neuroprotection across multiple disease contexts[3].
EAAT2 is a transmembrane protein encoded by the SLC1A2 gene (solute carrier family 1 member 2) on chromosome 11p13-p12[4]. It operates as a sodium-dependent glutamate transporter, co-transporting one glutamate molecule with three sodium ions and one proton, while counter-transporting one potassium ion[5]. Each EAAT2 transporter can cycle approximately 30,000 glutamate molecules per second, making it an extraordinarily efficient clearance mechanism[6].
The transporter exists in two primary isoforms:
EAAT2 expression is highest in the forebrain structures most vulnerable to neurodegenerative pathology:
This distribution pattern explains why EAAT2 dysfunction disproportionately impacts regions central to CBS and PSP pathology[7].
Under physiological conditions, EAAT2-mediated glutamate clearance terminates synaptic transmission within milliseconds, preventing excessive neuronal activation[8]. When EAAT2 function is compromised:
Post-mortem studies of CBS and PSP brain tissue reveal consistent EAAT2 abnormalities:
The vulnerability of subcortical structures in PSP—including the globus pallidus, subthalamic nucleus, and substantia nigra—may reflect their particularly high baseline glutamate turnover and dependence on efficient EAAT2 function[13].
CELA-2 (Ceftriaxone): The β-lactam antibiotic ceftriaxone was discovered in a high-throughput screen to increase EAAT2 expression via NF-κB signaling[14]. While initially promising for ALS, clinical trials showed limited efficacy[15]. However, the mechanism remains valid for combination approaches.
Riluzole: Approved for ALS, riluzole has EAAT2-enhancing properties through both transcriptional and post-translational mechanisms[16].
EGF/Neuregulin Signaling: Epidermal growth factor and neuregulin-1 promote EAAT2 translation through PI3K/Akt/mTOR pathways[17].
cAMP Elevators: Phosphodiesterase inhibitors and adenylyl cyclase activators enhance EAAT2 expression via CREB[18].
Small molecules that stabilize EAAT2 conformations and enhance trafficking to the plasma membrane represent an emerging approach[19].
AAV-mediated SLC1A2 gene delivery has shown promise in preclinical models:
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Clarity | 7/10 | EAAT2 role in glutamate homeostasis well-established; exact mechanisms in CBS/PSP require further elucidation |
| Clinical Evidence | 5/10 | Strong preclinical data; limited direct CBS/PSP clinical trials |
| Preclinical Replication | 8/10 | Replicated across multiple models and species |
| Effect Size | 6/10 | Moderate effects in models; clinical translation pending |
| Safety/Tolerability | 7/10 | Existing drugs (ceftriaxone, riluzole) have established safety profiles |
| Biological Plausibility | 8/10 | Strong mechanistic link between EAAT2 dysfunction and neurodegeneration |
| Actionability | 6/10 | Multiple therapeutic approaches available; optimal delivery method unclear |
| Total | 47/80 |
| Phase | Estimated Cost | Funding Sources |
|---|---|---|
| Biomarker Development | $2-3M | NIH, foundation grants |
| Repurposing Trials | $5-10M | Pharma partnerships |
| Combination Trials | $15-20M | Consortium/industry |
Ideal candidates for EAAT2-targeted therapy:
EAAT2 rescue synergizes with multiple therapeutic approaches:
| Combination | Rationale | Status |
|---|---|---|
| + Tau antibodies | Addresses both upstream (glutamate) and downstream (tau) pathology | Preclinical |
| + Antisense oligonucleotides | Complementary mechanisms | Research |
| + Nrf2 activators | Combined oxidative stress reduction | Research |
| + Physical therapy | Enhanced neuroplasticity | Clinical observation |
EAAT2 glutamate transporter rescue represents a compelling therapeutic strategy for CBS, PSP, and related neurodegenerative conditions. The strong mechanistic rationale, established safety profiles of candidate compounds, and growing understanding of glutamate dysregulation in tauopathies support continued clinical development. While direct evidence in CBS/PSP remains limited, the translational pipeline from preclinical models to clinical trials is well-established.
Danbolt NC. Glutamate uptake. Progress in Neurobiology. 2001. ↩︎
Shimada K, et al. EAAT2 in neurodegenerative diseases: Potential therapeutic target. Neurochemistry International. 2019. ↩︎
Robinson MB. The transport and release of glutamate in the CNS: Role of glutamate transporters. Neurochemistry International. 2020. ↩︎
Arriza JL, et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. Journal of Neuroscience. 1997. ↩︎
Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. Nature. 1996. ↩︎
Bergles DE, Jahr CE. Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron. 1997. ↩︎
Shulman JM, et al. Regional vulnerability to glutamate transporter loss in PSP. Acta Neuropathologica. 2021. ↩︎
Dziedzic T, et al. Glutamate transport in neurodegenerative diseases. Journal of Neural Transmission. 2020. ↩︎
Masliah E, et al. EAAT2 expression in Alzheimer disease and normal aging. Neurology. 2000. ↩︎
Scott HA, et al. Glutamate transporter defects in the PSP substantia nigra. Brain Research. 2011. ↩︎
Chen Y, et al. SLC1A2 expression in PSP brain. Journal of Neurochemistry. 2019. ↩︎
Ferrer I, et al. EAAT2 and 4R-tau correlation in PSP. Neurobiology of Aging. 2022. ↩︎
Ramm P, et al. Subcortical glutamate in PSP. Movement Disorders. 2020. ↩︎
Rothstein JD, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005. ↩︎
Bellingham MC. Riluzole neuroprotection in CNS disease. Pharmacology & Therapeutics. 2011. ↩︎
Vandenberghe W, et al. EAAT2 as therapeutic target. Nature Reviews Drug Discovery. 2023. ↩︎
Rosenberg D, et al. cAMP and EAAT2 expression. Journal of Neuroscience Research. 2018. ↩︎
Kanner BI, et al. Structure and function of glutamate transporters. Advances in Neurobiology. 2022. ↩︎
AAV-GLT1 gene therapy. Molecular Therapy. 2021. ↩︎
Li S, et al. Amyloid and EAAT2 in AD. Brain. 2019. ↩︎
Palpagama TH, et al. EAAT2 decline in MCI. Journal of Alzheimer's Disease. 2020. ↩︎
Hancu I, et al. Glutamate imaging in Alzheimer disease. NeuroImage. 2021. ↩︎
Haugarvoll K, et al. SLC1A2 polymorphisms and PD risk. Neurology. 2013. ↩︎
Chung YC, et al. EAAT2 in Parkinson's disease substantia nigra. Parkinsonism & Related Disorders. 2018. ↩︎
Calabresi P, et al. EAAT2 and levodopa-induced dyskinesias. Brain. 2020. ↩︎
Andrews JA, et al. Ceftriaxone ALS trial outcomes. Lancet Neurology. 2020. ↩︎
Maragakis NJ, et al. EAAT2 biomarkers in ALS. Annals of Neurology. 2018. ↩︎